title: [Antithrombotic treatment in hypertensive patients with chronic atrial fibrillation. CARDIOTENS 99 study].
abstract: BACKGROUND
  Our main goals were to know the actual degree of oral anticoagulation and antiaggregation in hypertensive patients with atrial fibrillation in the daily clinical practice in Spain and to analyze any differences between primary care physicians and cardiologists.
  
  
  METHODS
  32,051 outpatients attended the same day by 1,159 physicians (21% cardiologists) were prospectively included in a database taking into account a history of hypertension and atrial fibrillation, demographic data and ongoing treatments.
  
  
  RESULTS
  Hypertension was detected in 10,555 patients and 999 of them had both hypertension and atrial fibrillation (9.46%: 435 males [44%] and 564 females [56%]). 53% patients were attended by primary care physicians and the rest by cardiologists. 33% of hypertensive patients with atrial fibrillation were on oral anticoagulation: 41% of them attended by cardiologists and 26% by primary care physicians (p < 0.05). These differences persisted when the patients were compared on the basis of their age. 39% of hypertensive patients were on oral antiaggregation treatment, without differences in both groups except for those aged less than 65 years who were found to receive more antiaggregation in primary care (36% vs 24%; p < 0.05).
  
  
  CONCLUSIONS
  The prevalence of atrial fibrillation in hypertensive patients is about 10%; there is a suboptimal degree of utilization of oral anticoagulation, which is more evident in patients attended by primary care physicians; elderly patients (> 80 years-old) were found to receive less anticoagulants and more antiaggregants both in primary health-care and cardiology health-care.
authors.affiliation: Sección de Cardiología, Hospital Universitario San Juan, Alicante, Spain.
authors.forename: Vicente
authors.initials: V
authors.lastname: Bertomeu Martínez
authors.forename: Pedro J
authors.initials: PJ
authors.lastname: Morillas Blasco
authors.forename: José Ramón
authors.initials: JR
authors.lastname: González Juanatey
authors.forename: Eduardo
authors.initials: E
authors.lastname: Alegría Ezquerra
authors.forename: José María
authors.initials: JM
authors.lastname: García Acuña
authors.forename: Isidoro
authors.initials: I
authors.lastname: González Maqueda
authors.forename: Araceli
authors.initials: A
authors.lastname: Frutos García
authors.forename: Ricardo
authors.initials: R
authors.lastname: Valero Parra
authors.forename: José Angel
authors.initials: JA
authors.lastname: Rodríguez Ortega
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001281:Atrial Fibrillation / Q000150:complications*; D002908:Chronic Disease; D003430:Cross-Sectional Studies; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000150:complications*; D008297:Male; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*
chemical_list: D005343:Fibrinolytic Agents